Company Overview and News


Add ONXEO
to your dashboard

Headline News

Onxeo Establishes U.S. Subsidiary

2016-03-21 biospace
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the creation of a U.S. subsidiary, based in New York City. The company also announced that experienced industry executive Philippe Maitre will head the U.S. subsidiary with the title of Executive VP & Chief of U.S. Operations. The U.S. subsidiary, to be named Onxeo US, will provide services to Onxeo as the company expands its development programs and establishes closer ties with the scientific and financial communities in the U.

GenSpera Form S-1/A

2016-01-23 sec.gov
    As filed with the Securities and Exchange Commission on January 22, 2016   Registration No. 333-208918     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   GENSPERA, INC. (Exact name of registrant as specified in its charter)   Delaware   2834   20-0438951 (State or jurisdiction of incorporation or organization)   (Primary Standard Industrial Classification Code Number)   (I.